Inhibition of Ca2+/calmodulin-dependent protein kinase II, RAS-GTPase and 20-hydroxyeicosatetraenoic acid attenuates the development of diabetes-induced vascular dysfunction in the rat carotid artery

Pharmacol Res. 2005 Sep;52(3):252-7. doi: 10.1016/j.phrs.2005.04.001.

Abstract

Diabetes causes accelerated vascular dysfunction through mechanisms that are poorly understood. This study examined the role of Ca2+/calmodulin-dependent protein kinase II (CaMKII), Ras-GTPase and 20-hydroxyeicosatetraenoic acid (20-HETE) in the development of abnormal reactivity to vasoactive agents in the carotid artery of diabetic rats. The vasoconstrictor response induced by endothelin-1 (ET-1) was significantly increased, whereas vasodilator response to carbachol was significantly reduced in the carotid artery segments of the STZ-diabetic rats. In contrast, the vasoconstrictor response to depolarization of the carotid arterial rings with 50mM KCl was similar in control and diabetic animals. Chronic intraperitoneal administration of KN-93 (5 mg/kg/alt diem), an inhibitor of CaMKII, FPTIII (1.5 mg/kg/alt diem), an inhibitor of Ras-GTPase, and inhibitors of 20-HETE formation 1-aminobenzotriazole (ABT, 50 mg/kg/alt diem) and N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine (HET0016, 2.5mg/kg/day), produced significant normalization of the altered agonist-induced vasoconstrictor and vasodilator responses without affecting blood glucose levels. All the inhibitors were administered for 4 weeks starting from the day 1 of diabetes induction. Inhibition of CaMKII, Ras-GTPase or 20-HETE formation did not affect the agonist-induced vasoconstrictor and vasodilator responses in the non-diabetic control animals. These data indicate that chronic blockade of CaMKII, Ras-GTPase or the production of 20-HETE normalizes the altered vascular reactivity to ET-1 and carbachol in the carotid artery of STZ-induced diabetic rats.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidines / pharmacology
  • Animals
  • Benzylamines / pharmacology
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors*
  • Carotid Arteries / drug effects*
  • Carotid Arteries / physiopathology
  • Carotid Artery Diseases / prevention & control
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / complications*
  • Diabetes Mellitus, Experimental / physiopathology
  • Hydroxyeicosatetraenoic Acids / antagonists & inhibitors*
  • Monomeric GTP-Binding Proteins / antagonists & inhibitors*
  • Organophosphonates / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Wistar
  • Streptozocin
  • Sulfonamides / pharmacology
  • Triazoles / pharmacology
  • Vascular Diseases / prevention & control
  • Vasoconstriction
  • Vasodilation

Substances

  • 2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium
  • Amidines
  • Benzylamines
  • HET0016
  • Hydroxyeicosatetraenoic Acids
  • Organophosphonates
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Triazoles
  • KN 93
  • 1-aminobenzotriazole
  • Streptozocin
  • 20-hydroxy-5,8,11,14-eicosatetraenoic acid
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Calcium-Calmodulin-Dependent Protein Kinases
  • Monomeric GTP-Binding Proteins